Associated tags: Biotechnology, Infection, Plasma, Hemoglobin, Serum, Chemistry
Locations: BRAY CO WICKLOW, WICKLOW, IE, KENYA, SG, AFRICA, IRELAND
CGM,
Consultant,
Negotiation,
Conference,
Growth,
Data analysis,
HIV,
Himawari (satellites),
Diabetes,
World Health Organization,
Acquisition,
American depositary receipt,
Diagnosis of HIV/AIDS,
Units of paper quantity,
Clinical trial,
Injection,
Balance sheet,
Waveform,
Pharmaceutical industry DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
Key Points:
- DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates.
- We expect to have fully executed this change by the end of 2024 and expect this will deliver significant annualised savings.
- The assets and liabilities attributable to Fitzgerald Industries have been removed from our Consolidated Balance Sheet as of December 31, 2023.
- Total revenues for Q4, 2023 were $13.4m which compares to $15.7m in Q4, 2022, a decrease of 14.6% and which were broken down as follows:
DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET.
Key Points:
- DUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET.
DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.
Key Points:
- DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc.
- (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company's American Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00 per ADS.
- The Nasdaq staff made this determination of compliance after the closing bid price of the Company's was at $1.00 per share or greater for the prior 10 consecutive business days.
- Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1) and Nasdaq considers the prior bid price deficiency matter now closed.
Retrieved on:
Thursday, February 15, 2024
(NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS representing four (4) Class A ordinary shares to one (1) ADS representing twenty (20) Class A ordinary shares.
Key Points:
- (NASDAQ: TRIB) (the “Company”) today announced that it has finalized the effective date of its ratio change of its American depositary shares (“ADSs”) from one (1) ADS representing four (4) Class A ordinary shares to one (1) ADS representing twenty (20) Class A ordinary shares.
- The effect of the ratio change on the ADS trading price on the Nasdaq Global Market is expected to take place at the open of trading on February 23, 2024 (U.S. Eastern Time) (the “Effective Date”).
- For Trinity Biotech Plc ADS holders, the change in the ADS ratio on February 23, 2024 will have the same effect as a one-for-five reverse ADS split and is intended to enable the Company to regain compliance with the $1.00 Nasdaq minimum bid price requirement and maintain its NASDAQ listing.
- Other than the change of effective date to February 23rd, 2024, the remaining details regarding the ratio change remain the same as previously announced on February 13, 2024.
Retrieved on:
Tuesday, February 13, 2024
(NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing four (4) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.
Key Points:
- (NASDAQ: TRIB) (the “Company”) today announced that it plans to change the ratio of the American depositary shares (“ADSs”) representing its Class A ordinary shares from one (1) ADS representing four (4) Class A ordinary share to one (1) ADS representing twenty (20) Class A ordinary shares.
- For Trinity Biotech Plc ADS holders, the change in the ADS ratio will have the same effect as a one-for-five reverse ADS split and is intended to i) enable the Company to regain compliance with the $1.00 Nasdaq minimum bid price requirement, and ii) facilitate investment from a broader pool of potential investors, who may have previously been unable to invest due to the ADSs trading below a price of $1.00.
- No fractional new ADSs will be issued in connection with the change in the ADS ratio.
- As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than five times the ADS price before the change.
Retrieved on:
Thursday, February 8, 2024
DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024.
Key Points:
- DUBLIN, Ireland, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024.
- The Company invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference.
- Please see the presentation information below.
Retrieved on:
Wednesday, February 7, 2024
(Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
Key Points:
- (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
- It is estimated that up to approximately 3 million people in the US have Sjögrens Syndrome, making it one of the most prevalent autoimmune syndromes.
- The Early Sjögrens Syndrome Test Panel is a valuable immunological tool for clinicians to both identify patients earlier, when therapeutic intervention is most effective, and to also identify patient cohorts most at risk of progression to Sjögren’s Syndrome.
- A PLA code is a distinct, specific code assigned to a particular test and approved by the American Medical Association’s (AMA) Current Procedural Terminology (CPT) Editorial Panel.
Retrieved on:
Wednesday, January 31, 2024
USAID,
Interim,
Growth,
ADS,
CFO,
Consultant,
CGM,
HIV,
Diabetes,
Intellectual property,
Glucose meter,
Interim management,
American depositary receipt,
Waveform,
Service management,
Des Fitzgerald,
Acquisition,
Units of paper quantity,
Base rate,
Q4,
Pharmaceutical industry DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
Key Points:
- DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
- In our HIV business, shipments of Uni-Gold are expected to be lower than Q3, 2023 due to the typical irregular quarter on quarter ordering patterns in that business.
- At June 30, 2023 and September 30, 2023, the assets and liabilities attributable to Fitzgerald Industries have been de-recognised from the Consolidated Balance Sheet.
- Total revenues for Q3, 2023 were $14.7 million which compares to $15.7 million in Q3, 2022, a decrease of 6.5% and which were broken down as follows:
Retrieved on:
Wednesday, January 31, 2024
Partnership,
ADS,
CGM,
History,
HIV,
Innovation system,
Biomarker,
Pain,
Glucose meter,
Dexcom,
Trinity,
World Health Organization,
Trauma,
Bayer,
American depositary receipt,
Acquisition,
Base rate,
EST,
Health,
Security (finance) DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (“CGM”) assets of privately held Waveform Technologies, Inc. (“Waveform”) for $12.5 million in cash, 9 million American Depositary Shares (“ADSs”) of the Company and additional contingent consideration.
Key Points:
- Waveform will no longer sell the Cascade device and the Company will not sell that device in its current form.
- The remaining $9.5 million is available for general corporate purposes including for the further development of the CGM and biosensor technologies.
- Waveform is part of a portfolio company of Perceptive and the 9 million ADS being issued by the Company as partial consideration for the acquisition of the Waveform assets will be issued to Perceptive.
- The Company will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.
Retrieved on:
Wednesday, January 31, 2024
Partnership,
Public,
CGM,
Diabetes,
Patient,
Glucose meter,
Trinity,
Physician,
Bayer,
Waveform,
Acquisition,
Letter,
EST,
Type 2 diabetes,
Pharmaceutical industry Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
Key Points:
- Both parties intend to negotiate a definitive agreement under the framework set by the Letter of Intent in the coming months.
- In addition to the proposal to enter the Chinese market, the Letter of Intent includes a framework for the intention to launch a CGM device in India.
- To date, CGM use in India is not widespread, but has been trending higher recently with increasing awareness about self-care.
- Trinity Biotech will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.
